Drug Approval | July 13, 2024
Lupin receives EIR from USFDA for its Dabhasa facility
The facility is a part of Lupin Manufacturing Solutions
The facility is a part of Lupin Manufacturing Solutions
Utidelone can penetrate BBB due to its unique physicochemical characteristics and insusceptibility to P-glycoprotein-mediated efflux
Acquisition provides Ligand with the royalty rights to QARZIBA, a highly differentiated, commercial oncology drug marketed in 35 countries by global pharmaceutical company Recordati S.p.A.
This strategic decision will unlock significant value for our scientific and industrial products business
GAAP net loss of $1.2 billion and GAAP diluted EPS of $(3.07)
FDA has concluded that this inspection is 'closed'
The Gold Medal distinction places the company in the top 5% of all organizations assessed within EcoVadis's rigorous framework globally
Sun Pharma's Dadra facility receives OAI status from US FDA
Approximately half of all patients with metastatic breast cancer (mBC) express low levels of HER2
Asahi Songwon Colors' shareholding in ALSPL has increased from 78% to 100%
Subscribe To Our Newsletter & Stay Updated
